Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. (Q38061501)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

review article

1 reference

title

Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Adrián Llerena

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Adrián Llerena

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Miguel Bernardo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Jerónimo Saíz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Amalia Lafuente

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

1 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

1773-1782

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

Evaluation of treatment-resistant schizophrenia

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Relapse in schizophrenia: costs, clinical outcomes and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

The promise and reality of pharmacogenetics in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

A pharmacogenomics primer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Pharmacogenetics in psychiatry: translating research into clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Genomewide association study of movement-related adverse antipsychotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Genome-wide association study of antipsychotic-induced QTc interval prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Uncovering the roles of rare variants in common disease through whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

MDR1 gene polymorphisms and response to acute risperidone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Genetic association between TNF-alpha -308 G>A polymorphism and longitudinal weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Medication adherence: a review of the literature and implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

Pharmacogenetic considerations in the treatment of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.159

21 January 2018

Identifiers

DOI

10.2217/PGS.12.159

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23171340%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference